

Product datasheet for **TL317209V**

WVOX Human shRNA Lentiviral Particle (Locus ID 51741)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	WVOX Human shRNA Lentiviral Particle (Locus ID 51741)
Locus ID:	51741
Synonyms:	D16S432E; DEE28; EIEE28; FOR; FRA16D; HHCMA56; PRO0128; SCAR12; SDR41C1; WOX1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	WVOX - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001291997 , NM_016373 , NM_018560 , NM_130788 , NM_130790 , NM_130791 , NM_130792 , NM_130844 , NR_120435 , NR_120436 , NM_130791.1 , NM_130791.2 , NM_130791.3 , NM_130844.1 , NM_130844.2 , NM_016373.1 , NM_016373.2 , NM_016373.3 , NM_001291997.1 , NM_018560.4 , NM_130790.1 , BC003184 , NM_001291997.2 , NM_130791.4 , NM_016373.4
UniProt ID:	Q9NZC7
Summary:	This gene encodes a member of the short-chain dehydrogenases/reductases (SDR) protein family. This gene spans the FRA16D common chromosomal fragile site and appears to function as a tumor suppressor gene. Expression of the encoded protein is able to induce apoptosis, while defects in this gene are associated with multiple types of cancer. Disruption of this gene is also associated with autosomal recessive spinocerebellar ataxia 12. Disruption of a similar gene in mouse results in impaired steroidogenesis, additionally suggesting a metabolic function for the protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).